Rosenbaum M, Malbon C C, Hirsch J, Leibel R L
Laboratory of Human Behavior and Metabolism, Rockefeller University, New York, New York 10021.
J Clin Endocrinol Metab. 1993 Aug;77(2):352-5. doi: 10.1210/jcem.77.2.8393882.
Human adipocytes are responsive to both alpha- (antilipolytic) and beta-(lipolytic) actions of catecholamine agonists. These effects are mediated by G proteins which interact with adenylcyclase beta 1- and beta 2-adrenoreceptor (AR) subtypes are identified in human adipose tissue. The existence of a third beta-adrenergic (beta 3) receptor has been recently proposed. The beta 3-AR has been reported to mediate catecholamine-induced cAMP accumulation and to be more responsive in this regard than either the beta 1- or the beta 2-AR. To examine the possibility that a beta 3-AR plays a significant role in the control of catecholamine-stimulated lipolysis in human adipose tissue, we used a sensitive in vitro measure of lipolysis. Abdominal and gluteal sc adipose tissue samples from 14 adults were incubated with isoproterenol, a nonspecific beta-AR agonist which activates adenylyl cyclase via all three beta-AR subtypes, in the presence of varying concentrations of a beta-AR antagonist, alprenolol, which blocks the beta 1- and beta 2-AR, but not the beta 3-AR. In tissue from both abdominal and gluteal sites, alprenolol (10(-3) M) completely abolished the lipolytic response to isoproterenol (10(-6) M). Alprenolol (10(-3) M) alone reduced basal lipolysis by 10.2 +/- 2.2% (SEM) in abdominal tissue (P < 0.01), and 7.1 +/- 2.7% in gluteal tissue (P < 0.05). In the presence of alprenolol (10(-3) M), isoproterenol (10(-6) M) had no demonstrable lipolytic effect. The probability of incorrect acceptance of the null hypothesis that isoproterenol had no effect on lipolysis in alprenolol-blocked tissue is P beta < 0.05 for both depots. As an additional control, pooled inguinal adipose tissue from adult male Sprague-Dawley rats was incubated with the same concentrations of alprenolol. Rat adipose tissue has been previously shown to express the beta 3-adrenoreceptor and lipolysis was increased in rat adipose tissue in the presence of alprenolol 10(-4) M and 10(-5) M. We conclude that beta 3-ARs, if present in human adipocyte plasma membranes, do not significantly affect rates of lipolysis.
人类脂肪细胞对儿茶酚胺激动剂的α-(抗脂解)和β-(脂解)作用均有反应。这些作用由G蛋白介导,G蛋白与腺苷酸环化酶相互作用,在人类脂肪组织中已鉴定出β1-和β2-肾上腺素能受体(AR)亚型。最近有人提出存在第三种β-肾上腺素能(β3)受体。据报道,β3-AR介导儿茶酚胺诱导的环磷酸腺苷(cAMP)积累,并且在这方面比β1-或β2-AR更敏感。为了研究β3-AR在控制人类脂肪组织中儿茶酚胺刺激的脂解作用中是否起重要作用,我们采用了一种敏感的体外脂解测量方法。将14名成年人腹部和臀部的皮下脂肪组织样本与异丙肾上腺素(一种非特异性β-AR激动剂,可通过所有三种β-AR亚型激活腺苷酸环化酶)一起孵育,同时加入不同浓度的β-AR拮抗剂阿普洛尔,该拮抗剂可阻断β1-和β2-AR,但不阻断β3-AR。在腹部和臀部组织中,阿普洛尔(10⁻³ M)完全消除了对异丙肾上腺素(10⁻⁶ M)的脂解反应。单独使用阿普洛尔(10⁻³ M)可使腹部组织的基础脂解降低10.2±2.2%(标准误)(P<0.01),使臀部组织的基础脂解降低7.1±2.7%(P<0.05)。在存在阿普洛尔(10⁻³ M)的情况下,异丙肾上腺素(10⁻⁶ M)没有明显的脂解作用。对于两个储存部位,在阿普洛尔阻断的组织中,异丙肾上腺素对脂解无影响这一零假设被错误接受的概率Pβ<0.05。作为额外对照,将成年雄性Sprague-Dawley大鼠的腹股沟脂肪组织汇集样本与相同浓度的阿普洛尔一起孵育。先前已证明大鼠脂肪组织表达β3-肾上腺素能受体,并且在存在10⁻⁴ M和10⁻⁵ M阿普洛尔的情况下,大鼠脂肪组织中的脂解增加。我们得出结论,即使人类脂肪细胞质膜中存在β3-AR,也不会显著影响脂解速率。